Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Increase in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 467,461 shares, an increase of 161.0% from the July 15th total of 179,105 shares. Approximately 4.2% of the company’s stock are sold short. Based on an average daily trading volume, of 2,318,553 shares, the short-interest ratio is currently 0.2 days.

Hong Kong Pharma Digital Technology Stock Up 1.5%

Shares of HKPD opened at $0.42 on Friday. The company has a 50 day simple moving average of $0.41 and a two-hundred day simple moving average of $0.57. Hong Kong Pharma Digital Technology has a 1 year low of $0.31 and a 1 year high of $2.58.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.04) EPS for the quarter. The business had revenue of $3.15 million for the quarter.

Institutional Investors Weigh In On Hong Kong Pharma Digital Technology

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.